Results 71 to 80 of about 25,087 (209)

Toward Predictable Nanomedicine: Current Forecasting Frameworks for Nanoparticle–Biology Interactions

Advanced Intelligent Discovery, EarlyView.
Predictive models successfully screen nanoparticles for toxicity and cellular uptake. Yet, complex biological dynamics and sparse, nonstandardized data limit their accuracy. The field urgently needs integrated artificial intelligence/machine learning, systems biology, and open‐access data protocols to bridge the gap between materials science and safe ...
Mariya L. Ivanova, Michael Nicholls, Nicola Russo, Gueorgui Mihaylov, Konstantin Nikolic   +4 more
wiley   +1 more source

CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator

Cell Death and Disease
BCL-2 inhibitors such as venetoclax offer therapeutic promise in acute myeloid leukemia (AML) and other cancers, but drug resistance poses a significant challenge. It is crucial to understand the mechanisms that regulate venetoclax response.
Lixia Zhang, Xinyue Zhou, Sajesan Aryal, Virginia Veasey, Pengcheng Zhang, Fu Jun Li, Yu Luan, Ravi Bhatia, Yang Zhou, Rui Lu   +9 more
doaj   +1 more source

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Haematologica, 2018
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia ...
Anthony R. Mato, Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Paul M. Barr, Alison R. Sehgal, Bruce D. Cheson, Clive S. Zent, Hande H. Tuncer, Stephen J. Schuster, Peter V. Pickens, Nirav N. Shah, Andre Goy, Allison M. Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M. Gashonia, Arun K. Singavi, Lindsey E. Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F. Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R. Furman, Chadi Nabhan   +47 more
doaj   +1 more source

Current perspectives in fragment based lead discovery (FBLD) [PDF]

, 2017
It is over 20 years since the first fragment-based discovery projects were disclosed. The methods are now mature for most ‘conventional’ targets in drug discovery such as enzymes (kinases and proteases) but there has also been growing success on more ...
Alvarez-Garcia, Bas Lamoree, Baurin, Bertrand, Boehm, Bollag, Chen, Chen, Congreve, Darby, Davies, English, Erlanson, Erlanson, Erlanson, Fischer, Giannetti, Goodford, Gossert, Hajduk, Hajduk, Hajduk, Hann, Hopkins, Howard, Hubbard, Hubbard, Hubbard, Hubbard, Jencks, Johnson, Keseru, Kozakov, Lau, Linke, Ludlow, Maurer, Meiby, Miller, Miranker, Nasiri, Nienaber, Oltersdorf, Ostrem, Parker, Paul Workman, Pearce, Renaud, Ringe, Rob L.M. van Montfort, Roderick E. Hubbard, Roughley, Ruiz-Carmona, Schiebel, Schiebel, Schulz, Shuker, Souers, Sun, Vivat   +59 more
core   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models

Cancer Medicine, 2021
Purpose Despite the availability of new drugs, many patients with acute myeloid leukemia (AML) do not achieve remission and outcomes remain poor. Venetoclax is a promising new therapy approved for use in combination with a hypomethylating agent or with ...
Ravendra Garg, Kevin J. H. Allen, Wojciech Dawicki, Eileen M. Geoghegan, Dale L. Ludwig, Ekaterina Dadachova   +5 more
doaj   +1 more source

Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation. [PDF]

EJHaem
ABSTRACT Introduction Acute myeloid leukemia (AML) with plasmacytoid dendritic cell differentiation (pDC‐AML) is a newly described subtype of leukemia with features resembling blastic plasmacytoid dendritic cell neoplasm (BPDCN). Case Presentation Herein, we present a case of pDC‐AML in which bone marrow findings were best classified as AML, whereas ...
Lee BJ, Griffin SP, Jeyakumar D, Gamayo A, Rezk SA, Naqvi K.   +5 more
europepmc   +2 more sources

Estudio de utilización de Ibrutinib en leucemia linfocítica crónica [PDF]

, 2019
La leucemia linfocítica crónica (LLC) es la leucemia más frecuente en nuestro país afectando mayoritariamente a mayores de 65 años. En los últimos años el tratamiento de la leucemia linfocítica crónica se ha visto modificado debido al ...
Beltrán Gómez, Inés
core  

Disarming the Hsp70–Bim Alliance: Small‐Molecule and Peptidic Disruptors of a Chaperone‐Apoptotic Switch in Cancer

ChemistryOpen, EarlyView.
Targeting a nucleotide‐sensitive groove on Hsp70 that binds the Bim BH3 helix, we integrate structures, biophysics, and SAR from peptides, fragments, and phenalene‐dicarbonitrile “wedges.” These disrupt the Hsp70–Bim complex with sub‐µM cellular engagement and in vivo activity while sparing Hsp90/mortalin.
Emadeldin M. Kamel, Mohammed Al‐zharani, Lina M. Alneghery, Noha A. Ahmed, Faris F. Aba Alkhayl, Al Mokhtar Lamsabhi   +5 more
wiley   +1 more source

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Blood Neoplasia
: The antiapoptotic protein myeloid cell leukemia 1 (Mcl-1) promotes cell survival in acute myeloid leukemia (AML), and its overexpression is associated with resistance to venetoclax.
Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids   +13 more
doaj   +1 more source